Selected Publications
DiNardo CD, Pratz KW, Panayiotidis P, Wei X, Vorobyev V, Illés Á, Kim I, Ivanov V, Ku G, Miller CL, Zhang M, Tatsch F, Potluri J, Schmidt X, Récher C: The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia Am J Hematol : 2024.
Connor MP, Prathapa N, Frey NV, Gill SI, Hexner EO, Bruno XJ, Lai CE, Loren AW, Luger SM, Matthews AH, McCurdy SR, Perl AE, Porter DL, Zeringue A, Oved JH, Olson TS, Pratz KW, Babushok DV: Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia Haematologica 109 (8): 2732-2737,2024.
12., Sastow D, Levavi H, Wagner N, Pratz K, Tremblay D: Ven the dose matters: Venetoclax dosing in the frontline treatment of AML Blood Rev : 2024.
Döhner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat V, Thirman MJ, Récher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, Pollyea DA: Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine Blood : 2024.
Hamilton KW, Hua E, Dutcher L, Fernandez Lynch H, Junker P, Doucette AG, Werner D, Kannel EZ, Civitello T, Gabriel P, Ahya VN, Jacobs DA, Garfall A, Pratz K, Degnan KO, Blumberg EA, Capozzi D, Craig E, Takach P, Payne AS, Geara A, Koenig H, Holzman L, Tebas P: Implementation of an Approach to Equitable Allocation of SARS-CoV-2 Monoclonal Antibodies for Preexposure Prophylaxis: Experience From a Single Medical Center Open Forum Infect Dis. 11 (8): 2024.
78., Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Liedtke M, Bergeron J, Wood BL, Zhao Y, Wu G, Chang TC, Zhang W, Pratz KW, Dinner SN, Frey N, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Patel SB, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Luger SM, Mullighan CG, Tallman MS: Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults N Engl J Med 391 (4): 320-333,2024.
Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Döhner H, Récher C, Fiedler W, Yamamoto K, Wang J, Yoon SS, Wolach O, Yeh SP, Leber B, Esteve J, Mayer J, Porkka K, Illés Á, Lemoli RM, Turgut M, Ku G, Miller C, Zhou Y, Zhang M, Chyla B, Potluri J, DiNardo CD, et al: Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia Am J Hematol 99 (4): 615-624,2024.
Berman E, Shah NP, Deninger M, Altman JK, Amaya M, Begna K, Bhatia R, Chan O, Collins R, Curtin P, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore J, Oehler V, Pratz K, Pusic I, Rose M, Shomali W, Smith BD, Styler M, Sweet K, Talpaz M, Tanaka T, Tantravahi S, Tsai S, Vaughn J, Welborn J, Yang D, Mauro M, Cortes J, Radich J, Druker B.: CML and the WHO: Why? J Clin Oncology 42 (9): 984-986,2024.
PRatz KW: Approaches for sAML Early Identification and Diagnosis Reach MD : 2024.
Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore JO, Oehler V, Pratz K, Pusic I, Rose MG, Shomali W, Smith BD, Styler M, Talpaz M, Tanaka TN, Tantravahi S, Thompson J, Tsai S, Vaughn J, Welborn J, Yang DT, Sundar H, Gregory K.: Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw 22 (1): 43-69,2024.
Academic Contact Information
3400 Civic Center Blvd.
South Pavilion Room 12-155
Philadelphia,
PA
19104
Patient appointments: 800-789-7366